Agents and Actions

, Volume 24, Issue 3–4, pp 297–302 | Cite as

Comparison of the effects of the ace inhibitors trandolapril and enalapril on phlogogen induced foot pad oedema in the rat

  • S. Jouquey
  • N. L. Brown
  • J. Fichelle
  • M. Worcel
Article

Abstract

Two angiotensin converting enzyme (ACE) inhibitors, trandolapril and enalapril, were compared for their effects on rat food-pad oedema induced by carrageenin, bradykinin dextran and platelet activating factor (PAF). Trandolapril (0.03–30.0 mg/kg, per os) potentiated carrageenin-induced oedemas. Enalapril produced the same effect at 3–10 fold higher doses (0.3–30.0 mg/kg per os). Both ACE inhibitors were equiactive in potentiating bradykinin-induced oedema. Neither compound affected dextran-induced oedema. In marked contrast PAF-induced oedema was reduced by both ACE inhibitors, trandolapril being approximately 10 fold more active than enalapril. The observed differences in potency between the two ACE inhibitors corresponded with their previously described actions on inhibition of plasma and tissue ACE and in inducing hypotension. The results suggest a crucial role of kinins in the oedemagenic response to carrageenin. The reason why the ACE inhibitors reduced PAF-induced oedema is not clear, but could involve peripheral vasodilation.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    C. A. Winter, E. A. Risley and G. W. Nuss,Carrageenin-induced oedema in hind paw of the rat as an assay for anti-inflammatory drugs, Proc. Soc. exp. Biol. Med.111, 544–547 (1962).PubMedGoogle Scholar
  2. [2]
    M. Di Rosa, J. P. Giroud and A. Willoughby,Studies of the mediators of the acute inflammatory response induced in rats in different sites by carrageenin and turpentine, J. Pathol.104, 15–29 (1971).CrossRefPubMedGoogle Scholar
  3. [3]
    M. P. Holsapple and G. K. W. Yim,Therapeutic reduction of ongoing carrageenin induced inflammation by lipoxygenase, but not cyclooxygenase inhibitors, Inflammation8, 223–230 (1984).CrossRefPubMedGoogle Scholar
  4. [4]
    G. P. Lewis,Kinins in inflammation and tissue injury. In:“Bradykinin, Kallidin and Kallikrein”. Handb. Exp. Pharmac, pp. 516–530 (Ed. E. G. Erdos). Springer-Verlag Berlin, Heidelberg (1970).Google Scholar
  5. [5]
    F. Marceau, A. Lussier, D. Reboli and J. P. Giroud,Pharmacology of kinins: their relevance to tissue injury and inflammation, Gen. Pharmac.14, 209–229 (1983).Google Scholar
  6. [6]
    J. Damas and G. Remacle-Volon,Role des kinines dans l'oedème tégumentaire déclenché par les carragénines chez le rat, J. Pharmacol. (Paris)13, 225–239 (1981).Google Scholar
  7. [7]
    H. Y. Yang, E. G. Erdos and Y. Levin,Characterization of a dipeptide hydrolase (kininase II: angiotensin converting enzyme), J. Pharmacol. Exp. Ther.177, 291–300 (1971).PubMedGoogle Scholar
  8. [8]
    A. L. A. Boura and A. P. Svolmanis,Converting enzyme inhibition in the rat by captopril is accompanied by potentiation of carrageenin-induced inflammation, Br. J. Pharmac.82, 3–8 (1984).Google Scholar
  9. [9]
    G. Caspritz, H. G. Alpermann and R. Schleyerbach,Influence of the new angiotensin converting enzyme inhibitor ramipril on several models of acute inflammation and the adjuvant arthritis in the rat, Arzneim.-Forsch./Drug Res.36, 1605–1608 (1986).Google Scholar
  10. [10]
    Y. Matsuno, H. Hori, M. Oka, H. Nakamura, T. Ito and T. Kadokowa,General pharmacology of the novel angiotensin converting enzyme inhibitor alacepril: effects on control nervous and sensory systems and on the other functions, Arzneim. Forsch./Drug Res.36, 62–68 (1986).Google Scholar
  11. [11]
    S. B. Hwang, M. H. Lam, C. L. Li and T. Y. Sen,Release of platelet activating factor and its involvement in the first phase of carrageenin-induced rat foot edema, European J. Pharmacol.120, 33–41 (1986).CrossRefGoogle Scholar
  12. [12]
    N. L. Brown, J. Fichelle, J. C. Vincent and M. Worcel,Cardiovascular profile of trandolapril a new angiotensin convertin enzyme (ACE) inhibitor, Br. J. Pharmac.90, 203P (1987).Google Scholar
  13. [13]
    N. L. Brown, C. Chevillard and M. Worcel,Difference between trandolapril and enalapril for inhibition of tissue ACE activity in rats, Br. J. Pharmac.90, 204P (1987).Google Scholar
  14. [14]
    D. A. Rowley and E. P. Benditt,5-Hydroxytryptamine and histamine as mediators of the vascular injury produced by agents which damage mast cells in rats, J. exp. Med.103, 399–411 (1956).CrossRefPubMedGoogle Scholar
  15. [15]
    S. Nishida, K. Kagawa and S. Tomizawa, Dextran-induced paw edema and 5-hydroxytryptamine release, Biochem. Pharmacol.28, 3149–3150 (1979).CrossRefPubMedGoogle Scholar
  16. [16]
    K. F. Swingle and M. J. Reiter,Inhibition of PAF-acether-induced edema of the rat's paw, Agents and Actions18, 359–365 (1986).CrossRefPubMedGoogle Scholar
  17. [17]
    J. Tamargo, T. Tejerina, C. Delgado and S. Barrigon,Electrophysiological effects of platelt-activating factor (PAF-acether) in guinea-pig papillary muscles, European J. Pharmacol.109, 219–227 (1985).CrossRefGoogle Scholar
  18. [18]
    C. V. Wedmore and T. J. Williams,Platelet-activing factor (PAF), a secretory product of polymorphonuclear leucocytes, increases vascular permeability of rabbit skin, Br. J. Pharmacol.74, 916P-917P (1981).Google Scholar
  19. [19]
    D. M. Humphrey, L. M. McManus, K. Satouchi, D. J. Hanahan and R. N. Pinckard,Vasoactive properties of acetyl glyceryl ether phosphorylcholine and analogues, Lab. Invest.46, 422–427 (1982).PubMedGoogle Scholar
  20. [20]
    J. Bjork, L. Lindbom, B. Gerdin, G. Smedegard, K. E. Arfors and J. Benveniste,Paf-acether (platelet activating factor) increases microvascular permeability and affects endothelium-granulocyte interaction in microvascular beds, Acta Physiol. Scand119, 305–308 (1983).PubMedGoogle Scholar
  21. [21]
    J. Bjork and B. Smedegard,Acute microvascular effects of PAF-acether, as studied by intravital microscopy, European J. Pharmacol.96, 87–94 (1983).CrossRefGoogle Scholar
  22. [22]
    C. S. Sweet, D. M. Gross, P. T. Arbegast, S. L. Gaul, P. M. Britt, C. L. Ludden, D. Weitz and C. A. Stone,Antihypertensive activity of N-[(S)-1-(ethoxycarbonyl)-3-phenylpropyl]-l-Ala-l-Pro (MK 421), an orally active converting enzyme inhibitor, J. Pharmacol. Exp. Ther.216, 558–566 (1981).PubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag 1988

Authors and Affiliations

  • S. Jouquey
    • 1
  • N. L. Brown
    • 1
  • J. Fichelle
    • 1
  • M. Worcel
    • 1
  1. 1.Centre de Recherches Roussel-UclafRomainvilleFrance

Personalised recommendations